56 studies on Selank curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 1,588 published Selank COA source records from third-party laboratories, covering 636 publicly attributable vendor identities. Across 1,433 records with positive numeric purity, the arithmetic mean is 99.66%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 1 positive purity results are below 90%; 50 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-13. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.00 | $5.00–$6.50 | $1.20 | 3 sources · 3 offers |
| 10 mg | $10.38 | $9.00–$13.00 | $1.04 | 4 sources · 4 offers |
| 30 mg | $16.00 | $16.00–$16.00 | $0.53 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-13. Aggregate calculated: 2026-10-18T09:33:16.472989+00:00. Calculation time is not a laboratory observation date.
Within that total, 483 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 27 | 99.6% | 0 of 22 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #2 | 14 | 99.78% | 0 of 14 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 14 | 99.67% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #119528 (99.65%) · #119232 (99.47%) · #120192 (99.47%) · #119667 (99.03%) · #119613 (99.77%) · #119471 (99.96%)
Precise chemical characterization is fundamental for any therapeutic agent, ensuring reproducibility in research and safety in potential clinical applications. Understanding Selank's exact molecular structure allows f…
Understanding the acute cognitive impacts of high-altitude hypoxia is crucial for safety and performance in various contexts, including mountaineering, military operations, and occupational tasks in high-altitude envi…
The successful demonstration of efficacy for either tDCS or tRNS could represent a significant breakthrough in the management of developmental dyslexia. If proven effective, these non-invasive brain stimulation techni…
This study provides compelling and quantitative evidence that Selank possesses the capability to effectively compensate for the long-lasting negative effects of antenatal hypoxia on both integrative brain activity and…
This research highlights Selank's potential as a novel anxiolytic or antipsychotic agent that can modulate dopamine system activity without directly binding to dopamine receptors, potentially offering a therapeutic pr…
This research provides compelling evidence for the anti-ulcer properties of Selank, suggesting its potential beyond its known anxiolytic (anti-anxiety) effects. The fact that its metabolites also contribute to this pr…
This study provides compelling evidence that Selank holds significant promise as a therapeutic agent for addressing the long-term neurological consequences of antenatal hypoxia. The ability to correct deficits in sens…
This research highlights Selank's potential as a novel therapeutic agent for Generalized Anxiety Disorder and neurasthenia, offering a dual benefit of anxiety reduction alongside anti-fatigue and psychostimulant effec…
This research highlights Selank's significant potential as a neuroprotective and cognitive-enhancing agent, particularly in conditions involving noradrenergic system dysfunction. Given that cognitive deficits are a ha…
These findings suggest that Selank possesses unique immunomodulatory properties, acting as a novel regulator of the immune response. This dual effect on IL-6 gene expression and protein concentration, alongside its im…
**Selank's antidepressant component adds a clinically meaningful dimension** to its established anxiolytic profile — clinicians and peptide users evaluating it purely as an anxiolytic may be underestimating its mood-r…
This research highlights the significant potential of Selank as a therapeutic agent for cognitive impairments resulting from early-life neurological damage. The ability of Selank to restore complex cognitive functions…
This research provides critical and actionable insights into the pharmacokinetics of glyprolines, underscoring that the chosen route of administration profoundly dictates their bioavailability to key target organs suc…
This research provides compelling evidence for Selank's potential as a broad-spectrum therapeutic agent for psychoemotional disturbances. Its ability to induce long-term compensation of both behavioral and cognitive d…
**Genetic and phenotypic background profoundly shapes selank's neurochemical footprint**, meaning a single dosing protocol cannot be assumed to produce uniform monoaminergic outcomes across individuals. For clinicians…
**Selank and MIF may accelerate functional neurological recovery after ICH independently of hematoma clearance**, pointing to a neuroprotective mechanism — possibly immunomodulatory — rather than a purely mechanical o…
This research underscores selank's potential as a promising therapeutic agent for conditions characterized by decreased serotonin metabolism. The observed ability of selank to rapidly enhance 5-HT metabolism in the br…
These findings highlight Selank's potential as a novel antiviral agent, particularly for influenza prevention. The ability of Selank to modulate the immune response by selectively upregulating IFN-alpha suggests a tar…
This research provides compelling evidence that Selank acts as a potent nootropic agent, significantly enhancing long-term memory stability. The observed modulation of serotonin metabolism offers a plausible mechanism…
This research significantly advances our understanding of Selank's mechanism of action, particularly its immunomodulating effects at the genetic level. Identifying Gly-Pro as a key pharmacophor for these effects opens…
This study provides a crucial mechanistic understanding of how Noopept and Selank exert their nootropic and anxiolytic effects by enhancing inhibitory neurotransmission in the hippocampus. By demonstrating that these …
This research identifies the enkephalin-opioid system as a critical modulator of Selank's anxiolytic actions, revealing a new dimension to its mechanism within the central nervous system (CNS). Understanding this intr…
This research provides a potential biochemical mechanism for Selank's known anxiolytic and nootropic effects. By modulating the activity of carboxypeptidases, Selank could directly influence the production and availab…
This research highlights Selank's potential as a promising therapeutic agent for cognitive enhancement and the treatment of memory impairment. Given its ability to counteract deficits caused by protein synthesis inhib…
This research provides crucial molecular insights into how Selank exerts its nootropic effects, linking its action to fundamental cellular processes like ion homeostasis and membrane protein function. Understanding th…
This research highlights Selank as a promising anxiolytic peptide with potential to specifically alleviate the distressing symptoms of Alcohol Withdrawal Syndrome (AWS). The ability of Selank to reduce both anxiety an…
This research significantly extends therapeutic possibilities for managing anxiety disorders by introducing Selank as a potentially superior alternative to traditional anxiolytics. The peptide's prolonged anxiolytic e…
The findings suggest that combining Selank with benzodiazepines could be a superior strategy for managing anxiety-spectrum disorders. For individuals using or considering benzodiazepines, **Selank may serve as a valua…
The findings reveal that how you take Selank fundamentally changes how it works in the brain. For users, this implies that an injection protocol and a nasal spray protocol are not interchangeable and may target differ…
This study provides a genetic basis for Selank's anxiolytic effects, moving beyond phenomenological similarity to benzodiazepines. For users, it suggests that **Selank's benefits may stem from a fundamental re-tuning …
The study revealed that Selank at 0.3 mg/kg effectively prevented the development of ethanol-induced hyperlocomotion, demonstrating a clear inhibitory effect on this stimulant behavior. This effect was similar to that…
This research suggests that Selank may not just be a standalone anxiolytic but could also serve as an adjunctive therapy to enhance the efficacy of traditional benzodiazepines like diazepam, especially in stress-induc…
This research suggests Selank's mechanism isn't a direct up- or down-regulation of GABAergic gene expression, but rather a modulatory one. For users, this implies **Selank may be more effective as an adjunct or potent…
This research provides crucial insights into the neurobiological mechanisms underlying Selank's known anxiolytic (anti-anxiety) properties. By specifically boosting inhibitory signals in the hippocampus, a brain regio…
This research highlights the potential of Selank as a therapeutic agent for managing non-motor symptoms, specifically anxiety, in Parkinson's disease, even in the presence of significant neurodegeneration. The fact th…
This study provides compelling evidence that Selank possesses significant hepatoprotective and antioxidant properties, effectively shielding the liver from the damaging effects of both acute and chronic restraint stre…
The identification of potent anticoagulant effects from glyproline peptides, particularly Selank, represents a significant step towards developing novel antithrombotic agents. Current anticoagulants often come with a …
These findings suggest that for healthy, unstressed individuals, Selank may not provide noticeable anxiolytic or cognitive-enhancing benefits. This challenges the notion of Selank as a universal nootropic or mood enha…
The findings suggest Selank could offer a more nuanced approach to managing anxiety by modulating the `GABA` system differently than classic benzodiazepines. For biohackers and clinicians, this highlights Selank's pot…
This research significantly expands the synthetic toolbox for creating bimetallic complexes featuring the unique isoselenocarbonyl ligand. The successful structural characterization of three new complexes (4, 5, and 7…
This research highlights Selank's potential as a therapeutic agent for managing stress-induced gut dysbiosis, which is increasingly recognized as a contributor to various health issues, including mental health disorde…
This study provides compelling evidence for Selank's potential as a potent hepatoprotective agent, offering a novel therapeutic strategy against liver damage caused by chronic psychological stress. Given the increasin…
This research provides compelling evidence that Selank can effectively protect against and potentially reverse ethanol-induced memory impairment and attention deficits, even after prolonged chronic alcohol exposure. T…
The presence of unapproved research peptides like Selank and Semax in seized products highlights a significant regulatory blind spot and potential public health risk. For peptide users and biohackers, this serves as a…
This research provides crucial insights into the neurobiological mechanisms underlying the known anxiolytic and nootropic effects of Selank and Semax. Understanding how these peptides modulate specific brain networks …
This study suggests that Selank may function as a potent immunomodulatory agent, specifically by counteracting the inflammatory cascade triggered by chronic psychological stress. For individuals using peptides to mana…
Free, no account — handy when you're working with Selank.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account